Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Chugai Nets Half-Year Revenue Rise on Milestone Income
July 28, 2017
-
REGULATORY Chuikyo Scrutiny Continues for Cost Calculation Pricing Formula
July 27, 2017
-
REGULATORY Chuikyo Members at Odds over How to Proceed with “CEA” Debate
July 27, 2017
-
BUSINESS Linzess Off to Solid Start, Astellas Eyes Big Indication Addition
July 26, 2017
-
BUSINESS Novartis Japan Revenue Nearly Hit Bottom, FY2016 Sales Down 3.7%: New Chief
July 25, 2017
-
BUSINESS (Update) Mitsubishi Tanabe to Buy Israel’s NeuroDerm for US$1.1 Billion
July 25, 2017
-
BUSINESS Mitsubishi Tanabe to Buy Israel’s NeuroDerm for US$1.1 Billion
July 24, 2017
-
BUSINESS Asahi Kasei Pharma to Expand Lineup in Orthopedic Field, Boost Osteoporosis Market Share through Once-Yearly Formulation of Reclast
July 24, 2017
-
ACADEMIA Hypertension Treatment Guidelines for Elderly Finalized with Recommendations on Dosage Reduction, Discontinuation
July 21, 2017
-
REGULATORY Panel OKs 42.12 Million Yen Price Tag for Drug Makers’ MID-NET Use in PMS
July 20, 2017
-
ORGANIZATION New Chuikyo Doctor Reps Question Drug Pricing Premiums, CEA Plan
July 19, 2017
-
BUSINESS Probe Finds No HQ Instruction for Improper Patient Info Acquisition in Xarelto Surveys, Bayer Execs Take 3-Month Pay Cuts
July 18, 2017
-
REGULATORY Drug Price Cut Only Way to Eke Out FY2018 Funding, though Pharmas Important: Top MD Bureaucrat
July 14, 2017
-
ACADEMIA JSHR to Conduct 20-Year Follow-Up Study in Up to 100,000 Patients to Determine Efficacy of H. Pylori Eradication Therapy at Preventing Stomach Cancer
July 14, 2017
-
REGULATORY Chuikyo Starts Debate on Interim Report on CEA, Industry Hearings Slated for Next Meeting
July 13, 2017
-
REGULATORY MHLW to Announce Data Required for Conditional Early Approval
July 12, 2017
-
ACADEMIA New Treatment GL for Advanced HCC to Be Issued in October, Will Recommend Nexavar for 1st-Line Treatment
July 11, 2017
-
BUSINESS Chugai, Osaka Univ. Immunology Collaboration Gets Underway
July 11, 2017
-
BUSINESS Astellas, Kyoto Univ. Poised to Speed Up Drug Discovery with All-Around Pact
July 10, 2017
-
BUSINESS RaQualia Aiming for Market Capitalization of 100 Billion Yen by Around 2020: CEO
July 10, 2017
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…